Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (13516)	8/18/1998 1:40:00 AM
From: Dale Meunier	Read Replies (2) \| Respond to of 23519

Hi everyone: I've lost 10's of thousands playing options on this company with the misguided hope that they would eventually learn from their mistakes. But after reading the latest 10Q filing by Vivus, I'm beginning to lose all hope for this company. Note the last two sentences from a section of their 10Q. These guys are the biggest bunch of f**k-ups I have ever seen (please excuse the language). I'm currently sitting on 50 Sept. 12.5 contracts and 40 Dec 15 contracts with little hope of ever seeing any of them in the money. The Company has limited experience in manufacturing and selling MUSE (alprostadil) in commercial quantities. Up until the commercial launch of sildenafil, the Company had initially experienced product shortages due to higher than expected demand and difficulties encountered in scaling up production of MUSE (alprostadil). The Company leased 90,000 square feet of space in New Jersey in which it has constructed additional manufacturing and testing facilities. The FDA and MCA authorized the Company to begin commercial production and shipment of MUSE (alprostadil) from its new facility in June and March 1998, respectively. With the added capacity, the Company does not anticipate capacity constraints in the foreseeable future. However, if the Company encounters further difficulties with its current manufacturing facility, capacity issues could arise, which would have a material adverse effect on the Company's business, financial condition and results of operations. The Company has recently experienced various manufacturing difficulties that have resulted in production and shipment delays and higher costs. In turn, revenues from the sale of MUSE (alprostadil) will be delayed, which will have a material adverse affect on the Company's business, financial condition and results of operations. I'm finished venting, so now I'll just go quietly back into the shadows. P.S. If you want to see how an incredibly well managed company looks after it's shareholders, go to the SI thread on Yogen Fruz and see post #607. I bought this little gem in Jan/97 at $3.10. With the recent pullback in the TSE, the stock dropped from $14.00 to $10.00, thus the response from management in post #607. Do your own DD and I'm certain you will all be impressed. Not trying to hype, just trying to give something back to all the Vivus followers. Good luck to us all!!!!